UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,423	10/12/2005	Keietsu Abe	4600-0112PUS1	1788
2292 7590 02/01/2007 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			EXAMINER	
			RAGHU, GANAPATHIRAM	
			ART UNIT	PAPER NUMBER
			1652	
SHORTENED STATUTORY	PERIOD OF RESPONSE	NOTIFICATION DATE	DELIVERY MODE	
31 DA	YS	02/01/2007	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Notice of this Office communication was sent electronically on the above-indicated "Notification Date" and has a shortened statutory period for reply of 31 DAYS from 02/01/2007.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)			
Office Action Commons	10/532,423	ABE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Ganapathirama Raghu	1652			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)⊠ Responsive to communication(s) filed on 12 O	ctober 2005.				
	<u>_</u>				
3) Since this application is in condition for allowar					
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4)⊠ Claim(s) 1-52 is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.	:	•			
7) Claim(s) is/are objected to.					
8) Claim(s) 1-52 are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examine	r.				
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:					
1.⊠ Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)		·			
1) Notice of References Cited (PTO-892)	4) Interview Summary				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da				
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	5)  Notice of Informal P 6)  Other:	аселс Аррисацоп			
S. Patent and Trademark Office					

Art Unit: 1652

## **DETAILED ACTION**

Claims 1-52 are pending in this application.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I: Claims 1-38 and 45, drawn to a method of degrading plastic in the presence of a biosurfactant, wherein the biosurfactant is a plastic-binding protein and a plastic degrading enzyme.

Group II: Claims 39-44, drawn to a transformant prepared by recombination with the use of at least one DNA selected from a group consisting of DNA comprising a gene encoding the surfactant, DNA comprising a gene encoding the plastic-binding protein and a DNA comprising the useful substance.

Group III: Claims 46-47, drawn to an isolated polynucleotide encoding a polypeptide of SEQ ID NO: 3 and having the function as the hydrophobin.

Page 3

Art Unit: 1652

Group IV: Claims 48-49, drawn to an isolated polynucleotide encoding a polypeptide of SEQ ID NO: 4 and having substantially the same function as the plastic-degrading enzyme.

Group V: Claims 48-49, drawn to an isolated polynucleotide encoding a polypeptide of SEQ ID NO: 5 and having substantially the same function as the plastic-degrading enzyme.

Group VI: Claims 50-51, drawn to an isolated polynucleotide encoding a polypeptide of SEQ ID NO: 6 and having substantially the same function as the plastic-binding protein.

Group VII: Claims 50-51, drawn to an isolated polynucleotide encoding a polypeptide of SEQ ID NO: 7 and having substantially the same function as the plastic-binding protein.

Groups VIII-XII: Claim 52, drawn to an isolated protein encoded by the gene of groups III-VII, wherein group VIII polypeptide is encoded by the polynucleotide of group III... so on and so forth and group XII polypeptide is encoded by the polynucleotide of group VII.

The inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following categories:

Art Unit: 1652

- 1) A product and a process specially adapted for the manufacture of said product or
- 2) A product and process of use of said product; or
- 3) A product, a process specially adapted for the manufacture of said product and a use of said product; or
- 4) A process and an apparatus or means specifically adapted for carrying out the said process; or
- 5) A product, a process specially adapted for the manufacture of said product and an apparatus or means specifically designed for carrying out the said process.
- 37 CFR 1.475(c) states: If an application contains more or less than one of the combination of categories of in an invention set forth in paragraph (b) of this section, unity of invention might not be present.

In addition, the PCT does not provide for multiple products or methods within single application, therefore, unity of invention is lacking with regard to Groups I-XI; see 37 CFR 1.475. 37 CFR 1.475 (d) also states: If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims of the application and the first recited invention of each other categories related thereto will be considered as the main invention in the claims, see PCT Article 17(3)(a) 1.47(c).

37 CFR 1.475(e) further states; the determination whether a group of invention is so linked as to form a single inventive concept shall be without regard to whether the inventions are claimed in separate claims or as alternative within a single claim.

Application/Control Number: 10/532,423

Art Unit: 1652

In the instant application the products of groups III-XII differ substantially from one another to the extent that they have a different structure and function. The polynucleotides of groups III-VII encode polypeptides of groups VIII-XII that have different catalytic activities, substrate specificity and selectivity. The above products can be used exclusive of each other such that they do not share unity of invention under 37 CFR 1.475.

Furthermore, the inventions listed as Groups I-XII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical features linking the inventions of Group I-XII appears to be that they all relate to a method of degrading plastic in the presence of a biosurfactant, wherein the biosurfactant is a plastic-binding protein and a plastic degrading enzyme. However, Akutsu et al., (Appl. & Environ. Microbiol., 1988, Vol. 64 (1): 62-67) disclose a polyester polyurethane (PUR)-degrading enzyme with surface binding domain and an esterase enzyme activity. The reference also discloses the method of making and using said polypeptide.

Therefore the technical features linking the inventions of Group I-XII does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Accordingly, Groups I-XII are not so linked by the same or a corresponding special technical feature as to form a single inventive concept.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 10/532,423

Art Unit: 1652

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

## Rejoinder of restricted inventions

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitation of the allowable product claim will be rejoined in accordance with the provisions of M.P.E.P. 821.04. Process claims that depend from or otherwise include all the limitation of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after allowance are governed by 37 C.F.R. 1.312.

In the event of a rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 C.F.R. 1.104. thus, to be allowable, the rejoined claims must meet the criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. 103(b), 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that process claims should be amended during prosecution either to maintain dependency on the product claims or otherwise include the limitation of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See M.P.E.P. 804.01.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathirama Raghu whose telephone number is 571-272-4533. The examiner can normally be reached on 8 am - 4.30 pm EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of the application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ganapathirama Raghu, Ph.D. Patent Examiner Art Unit 1652 Jan. 29, 2007.

SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER